Zhao Ying-Ying, Xiang Qian-Ming, Chen Jia-Li, Zhang Li, Zheng Wei-Long, Ke Di, Shi Rong-Shu, Yang Kong-Wu
Department of Radiology, Affiliated Hospital of Zunyi Medical University, Zunyi, China.
Department of Radiology, Fuqing City Hospital Affiliated to Fujian Medical University, Fuqing, China.
Front Oncol. 2022 Oct 20;12:990247. doi: 10.3389/fonc.2022.990247. eCollection 2022.
It has been established that long-chain coding RNA (lncRNA) SLC25A25-AS1 is associated with cancer progression. However, the roles and mechanisms of SLC25A25-AS1 in prostate cancer (PC) have not been reported in the literature. The present study explored the relationship between SLC25A25-AS1 expression and PC progression comprehensive analysis. The pan-cancer expression of SLC25A25-AS1 was identified using data from The Cancer Genome Atlas (TCGA) database and tissue specimens from our hospital. The expression levels of SLC25A25-AS1 in various subgroups based on the clinical features were identified. The prognostic value of SLC25A25-AS1 and SLC25A25-AS1 co-expressed lncRNAs in PC patients was assessed by survival analysis and ROC analysis, and prognosis-related risk models of SLC25A25-AS1 were constructed. The relationship between SLC25A25-AS1 and the PC immune microenvironment was investigated using correlation analysis. SLC25A25-AS1 expression in PC was significantly increased and correlated with the T stage, clinical stage, Gleason score (GS), and dismal prognosis. SLC25A25-AS1 overexpression exhibited good performance in evaluating the prognosis of PC patients. The area under the curves (AUCs) of the 1-, 3-, and 5-year overall survival (OS) for SLC25A25-AS1 was 1, 0.876, and 0.749. Moreover, the AUCs for the 1-, 3-, and 5-year progress free interval (PFI) for SLC25A25-AS1 were 0.731, 0.701, and 0.718. SLC25A25-AS1 overexpression correlated with the infiltration of CD8 T cells, interstitial dendritic cells (IDC), macrophages and other cells. AC020558.2, ZNF32-AS2, AP4B1-AS1, AL355488.1, AC109460.3, SNHG1, C3orf35, LMNTD2-AS1, and AL365330.1 were significantly associated with SLC25A25-AS1 expression, and short OS and PFI in PC patients. The risk models of the SLC25A25-AS1-related lncRNAs were associated with a dismal prognosis in PC. Overall, SLC25A25-AS1 expression was increased in PC and related to the prognosis and PC immune microenvironment. The risk model of SLC25A25-AS1 have huge prospect for application as prognostic tools in PC.
已证实长链编码RNA（lncRNA）SLC25A25-AS1与癌症进展相关。然而，SLC25A25-AS1在前列腺癌（PC）中的作用和机制尚未见文献报道。本研究通过综合分析探讨了SLC25A25-AS1表达与PC进展之间的关系。利用来自癌症基因组图谱（TCGA）数据库的数据和我院的组织标本，确定了SLC25A25-AS1的泛癌表达。根据临床特征确定了SLC25A25-AS1在各个亚组中的表达水平。通过生存分析和ROC分析评估了SLC25A25-AS1和与SLC25A25-AS1共表达的lncRNAs在PC患者中的预后价值，并构建了SLC25A25-AS1的预后相关风险模型。采用相关性分析研究了SLC25A25-AS1与PC免疫微环境之间的关系。PC中SLC25A25-AS1的表达显著增加，且与T分期、临床分期、Gleason评分（GS）及不良预后相关。SLC25A25-AS1过表达在评估PC患者预后方面表现良好。SLC25A25-AS1的1年、3年和5年总生存期（OS）的曲线下面积（AUC）分别为1、0.876和0.749。此外，SLC25A25-AS1的1年、3年和5年无进展生存期（PFI）的AUC分别为0.731、0.701和0.718。SLC25A25-AS1过表达与CD8 T细胞、间质树突状细胞（IDC）、巨噬细胞等细胞的浸润相关。AC020558.2、ZNF32-AS2、AP4B1-AS1、AL355488.1、AC109460.3、SNHG1、C3orf35、LMNTD2-AS1和AL365330.1与SLC25A25-AS1表达、PC患者的短OS和PFI显著相关。SLC25A25-AS1相关lncRNAs的风险模型与PC的不良预后相关。总体而言，PC中SLC25A25-AS1表达增加，与预后及PC免疫微环境相关。SLC25A25-AS1风险模型作为PC预后工具具有巨大的应用前景。
